疯涨！知名基金经理高调看空？

Group 1: Market Overview - The Shanghai Composite Index has returned to 3,400 points, and the Hang Seng Tech Index is approaching a technical bull market, with the CRO and innovative drug sectors leading in gains [1] - Multiple Hong Kong innovative drug ETFs have seen year-to-date gains exceeding 50%, leading the ETF market [1][3] Group 2: Innovative Drug Sector Performance - After four years of deep correction, the Hong Kong innovative drug sector is experiencing a significant rebound, driven by the international expansion of innovative drugs [6] - The number of domestic new drugs selected for the 2025 ASCO annual meeting has reached a new high, with 74 research abstracts, including 34 oral presentations and 32 rapid oral presentations [6] - The market is showing considerable divergence regarding the current enthusiasm for the innovative drug sector, with some experts expressing caution [6][10] Group 3: IPO Activity in Hong Kong - The Hong Kong IPO market is currently very active, with 74 new stocks expected to be listed from June 8, 2024, to June 8, 2025, and 43 of these stocks trading above their issue prices [13] - The total amount raised through IPOs in Hong Kong has exceeded 776 billion HKD in the first five months of the year, a more than sevenfold increase compared to the same period last year [13] Group 4: Investment Sentiment - International investors are showing improved sentiment towards Chinese stocks, particularly in the "new consumption" and technology sectors [11] - Analysts suggest that the scarcity of assets in the Hong Kong market, particularly in sectors like the internet, new consumption, and innovative drugs, is contributing to its attractiveness [13]